Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,445 stopped studies mapped to Lymphoid Neoplasm and descendants · 89% state a reason
Over the 1,445 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).(pediTACTAL) | Phase 1 | withdrawn | Nov 26, 2021 | Baylor College of Medicine | Leadership determination | Other (stated, no rule matched) |
| NCT04860466 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory… | Phase 1 | terminated | Apr 27, 2021 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | — | withdrawn | Aug 30, 2022 | Dana-Farber Cancer Institute | Funding for study was withdrawn | Funding |
| NCT03710915 | A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma | Phase 1 | terminated | Oct 18, 2018 | HitGen Inc. | Company decision | Sponsor / business decision |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT04271930 | Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes | N/A | terminated | Feb 17, 2020 | Medical College of Wisconsin | This study terminated early due to lack of participant retention | Other (stated, no rule matched) |
| NCT03220347 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of… | Phase 1 | terminated | Jul 18, 2017 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04816526 | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma… | Phase 2 | terminated | Mar 25, 2021 | Cartesian Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT05315713 | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of… | Phase 1 / Phase 2 | terminated | Apr 7, 2022 | Hoffmann-La Roche | Study was terminated due to Sponsor decision. | Sponsor / business decision |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | — | withdrawn | Nov 24, 2014 | Wake Forest University Health Sciences | No patients enrolled | Enrollment / accrual |
| NCT05971056 | Providing Cancer Care Closer to Home for Patients With Multiple Myeloma | N/A | terminated | Aug 2, 2023 | Washington University School of Medicine | Insufficient funding | Funding |
| NCT04431635 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in… | Phase 1 | terminated | Jun 16, 2020 | University of Michigan Rogel Cancer Center | Loss of study funding | Funding |
| NCT02099539 | QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 31, 2014 | Altor BioScience | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02509039 | A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With… | Phase 1 | terminated | Jul 27, 2015 | Celgene | Replaced it with another clinical trial. | Other (stated, no rule matched) |
| NCT03136497 | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory… | Phase 1 | terminated | May 2, 2017 | Hackensack Meridian Health | Lack of enrollment | Enrollment / accrual |
| NCT02002598 | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Suzanne Lentzsch, MD | Slow accrual and loss of funding | Enrollment / accrual |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment… | Phase 2 | terminated | Dec 9, 2020 | Academic and Community Cancer Research United | Trial closed due to low accrual rate | Enrollment / accrual |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | Phase 1 | terminated | Oct 26, 2021 | Medical College of Wisconsin | Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All… | Other (stated, no rule matched) |
| NCT02978235 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple… | Phase 1 | terminated | Nov 30, 2016 | Taiho Oncology, Inc. | The trial was put on Clinical Hold and subsequently terminated prior to Phase 2 due to cases of… | Other (stated, no rule matched) |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation… | Phase 2 | withdrawn | Dec 22, 2016 | University of Arkansas | Study was not and will not be initiated due to lack of funding. | Funding |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801),… | Phase 1 | terminated | May 21, 2018 | Pfizer | A business decision was made by Pfizer to terminate the study. Termination was not due to any… | Safety / toxicity |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and… | Phase 1 | terminated | Jul 29, 2019 | Celgene | Slow accrual | Enrollment / accrual |
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904… | Phase 1 | terminated | Feb 2, 2022 | Hoffmann-La Roche | The study was terminated due to sponsor portfolio re-alignment. | Sponsor / business decision |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | Phase 1 / Phase 2 | terminated | Nov 28, 2013 | Columbia University | PI left institution | Investigator |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With… | Phase 1 / Phase 2 | terminated | Nov 16, 2018 | Celgene | Absence of significant therapeutic benefit over existing therapies | Other (stated, no rule matched) |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT01843868 | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP | N/A | withdrawn | May 1, 2013 | Australasian Leukaemia and Lymphoma Group | Study halted prematurely, prior to enrollment of first participant due to protracted logistical and… | Enrollment / accrual |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and… | Phase 1 | terminated | Feb 20, 2009 | Astex Pharmaceuticals, Inc. | The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in… | Safety / toxicity |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic… | — | terminated | Apr 21, 2021 | University of Washington | The study ended earlier than anticipated due to slow accrual. | Enrollment / accrual |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT05908396 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | terminated | Jun 18, 2023 | IGM Biosciences, Inc. | Company Decision | Sponsor / business decision |
| NCT01296555 | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in… | Phase 1 | terminated | Feb 15, 2011 | Genentech, Inc. | The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical… | Drug supply |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell… | Phase 1 | terminated | Mar 19, 2021 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Sep 10, 2019 | IGM Biosciences, Inc. | Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases… | Sponsor / business decision |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | May 4, 2022 | Mustang Bio | Business reasons | Sponsor / business decision |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell… | — | terminated | Dec 9, 2022 | Mustang Bio | Business Reasons | Sponsor / business decision |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With… | Phase 1 | terminated | Sep 14, 2018 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | Phase 1 | terminated | Jun 26, 2017 | Roncarolo, Maria Grazia, MD | Lack of Enrollment | Enrollment / accrual |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | Phase 1 / Phase 2 | terminated | Mar 9, 2022 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05050305 | Marizomib Central Nervous System (CNS) | Phase 2 | withdrawn | Sep 20, 2021 | Dana-Farber Cancer Institute | Study support withdrawn | Other (stated, no rule matched) |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | Phase 1 / Phase 2 | withdrawn | Jul 7, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual, no participants enrolled | Enrollment / accrual |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors,… | Phase 1 | terminated | Apr 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor Decision | Sponsor / business decision |
| NCT00838955 | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | Phase 2 | terminated | Feb 9, 2009 | Loyola University | There was lack of enrollment since January 2013 | Enrollment / accrual |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | Phase 2 | terminated | Mar 23, 2017 | Loyola University | Poor accrual | Enrollment / accrual |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple… | Phase 2 | withdrawn | Apr 20, 2023 | Washington University School of Medicine | Study sponsor decided to close study. | Sponsor / business decision |
| NCT02400242 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple… | Phase 1 | terminated | Mar 27, 2015 | Celgene | Lack of efficacy | Efficacy / futility |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and… | Phase 1 | terminated | Jun 22, 2021 | National Cancer Institute (NCI) | The study was terminated early because copanlisib was removed from the market by the Food and Drug… | Drug supply |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | Phase 1 / Phase 2 | terminated | Nov 20, 2014 | AHS Cancer Control Alberta | It did not show a significant benefit to justify completing the full target accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 22, 2024source: clinicaltrials